| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study
|
Solomon, Sunil Suhas
|
|
2016
|
3 |
4 |
p. e183-e190
nvt p.
|
article
|
| 2 |
Community viral load as an index of HIV transmission potential
|
Herbeck, Joshua
|
|
2016
|
3 |
4 |
p. e152-e154
nvt p.
|
article
|
| 3 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
|
Gallant, Joel E
|
|
2016
|
3 |
4 |
p. e158-e165
nvt p.
|
article
|
| 4 |
Good news for retention of women on option B+ in Malawi
|
Sibanda, Euphemia L
|
|
2016
|
3 |
4 |
p. e151-e152
nvt p.
|
article
|
| 5 |
Is HIV-1C a risk factor for protease inhibitor failure?
|
van Zyl, Gert U
|
|
2016
|
3 |
4 |
p. e149-e151
nvt p.
|
article
|
| 6 |
Is sub-Saharan Africa ready for pre-exposure prophylaxis?
|
Bernier, Adeline
|
|
2016
|
3 |
4 |
p. e154-e155
nvt p.
|
article
|
| 7 |
Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study
|
Haas, Andreas D
|
|
2016
|
3 |
4 |
p. e175-e182
nvt p.
|
article
|
| 8 |
Rethinking HIV pre-exposure prophylaxis prevention strategy
|
Kistan, Jesne
|
|
2016
|
3 |
4 |
p. e155-e157
nvt p.
|
article
|
| 9 |
Tenofovir alafenamide: safer, but questions remain
|
Boyd, Mark A
|
|
2016
|
3 |
4 |
p. e148-e149
nvt p.
|
article
|
| 10 |
UNGASS: time to put HIV at the forefront of drug policy
|
The Lancet HIV,
|
|
2016
|
3 |
4 |
p. e147-
1 p.
|
article
|
| 11 |
Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden
|
Häggblom, Amanda
|
|
2016
|
3 |
4 |
p. e166-e174
nvt p.
|
article
|
Journal description